Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

Lori Rink, Yuliya Skorobogatko, Andrew V. Kossenkov, Martin G. Belinsky, Thomas Pajak, Michael C. Heinrich, Charles D. Blanke, Margaret von Mehren, Michael F. Ochs, Burton Eisenberg and Andrew K. Godwin
Lori Rink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuliya Skorobogatko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew V. Kossenkov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin G. Belinsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Pajak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael C. Heinrich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles D. Blanke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret von Mehren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael F. Ochs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Burton Eisenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew K. Godwin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0193 Published August 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. Therefore, clinical management of GIST may benefit from further molecular characterization of tumors before and after imatinib mesylate treatment. As part of a recent phase II trial of neoadjuvant/adjuvant imatinib mesylate treatment for advanced primary and recurrent operable GISTs (Radiation Therapy Oncology Group S0132), gene expression profiling using oligonucleotide microarrays was done on tumor samples obtained before and after imatinib mesylate therapy. Patients were classified according to changes in tumor size after treatment based on computed tomography scan measurements. Gene profiling data were evaluated with Statistical Analysis of Microarrays to identify differentially expressed genes (in pretreatment GIST samples). Based on Statistical Analysis of Microarrays [False Discovery Rate (FDR), 10%], 38 genes were expressed at significantly lower levels in the pretreatment biopsy samples from tumors that significantly responded to 8 to 12 weeks of imatinib mesylate, that is, >25% tumor reduction. Eighteen of these genes encoded Krüppel-associated box (KRAB) domain containing zinc finger (ZNF) transcriptional repressors. Importantly, 10 KRAB-ZNF genes mapped to a single locus on chromosome 19p, and a subset predicted likely response to imatinib mesylate–based therapy in a naïve panel of GIST. Furthermore, we found that modifying expression of genes within this predictive signature can enhance the sensitivity of GIST cells to imatinib mesylate. Using clinical pretreatment biopsy samples from a prospective neoadjuvant phase II trial, we have identified a gene signature that includes KRAB-ZNF 91 subfamily members that may be both predictive of and functionally associated with likely response to short-term imatinib mesylate treatment. [Mol Cancer Ther 2009;8(8):2172–82]

  • gastrointestinal stromal tumors
  • imatinib mesylate
  • microarray
  • KRAB-ZNF genes

Footnotes

  • Grant support: NIH grants (CA106588 and a supplement from the Radiation Therapy Oncology Group to U10 CA21661; A.K. Godwin), LM009382 (M.F. Ochs), an award by the Fox Chase Cancer Center Translational Research Committee as part of the Fox Chase Cancer Center core grant (P30 CA006927; M. vonMehren and A.K. Godwin), and the NIH Training Grant (Institutional National Research Service Award) Appointment (CA009035-31; L. Rink).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received December 3, 2008.
    • Revision received May 4, 2009.
    • Accepted June 3, 2009.
  • © 2009 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (8)
August 2009
Volume 8, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Lori Rink, Yuliya Skorobogatko, Andrew V. Kossenkov, Martin G. Belinsky, Thomas Pajak, Michael C. Heinrich, Charles D. Blanke, Margaret von Mehren, Michael F. Ochs, Burton Eisenberg and Andrew K. Godwin
Mol Cancer Ther August 1 2009 (8) (8) 2172-2182; DOI: 10.1158/1535-7163.MCT-09-0193

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Lori Rink, Yuliya Skorobogatko, Andrew V. Kossenkov, Martin G. Belinsky, Thomas Pajak, Michael C. Heinrich, Charles D. Blanke, Margaret von Mehren, Michael F. Ochs, Burton Eisenberg and Andrew K. Godwin
Mol Cancer Ther August 1 2009 (8) (8) 2172-2182; DOI: 10.1158/1535-7163.MCT-09-0193
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PX-478 Radiosensitization in Pancreatic Cancer
  • Metronomic Gemcitabine Inhibits Pancreatic Cancer
  • p53-Deficient Cells Are More Sensitive to Plk1 Inhibitor
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement